Plasmatic and phenotypic effects with alirocumab, a PCSK9 inhibitor, in familial hypercholesterolemia treatment (FH)

Authors :: F. Simonelli
Simone Burocchi
Massimo Volpe
Barbara Fausta Filice
Vivanne Presta
Cristiano Miotti
Sofia Abbolito
Giovanna Gallo
Luciano De Biase
Gerardo Salerno
Source :: Atherosclerosis. 263:e246-e247
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: medicine.medical_specialty
familial hypercholesterolemia
business.industry
PCSK9
Familial hypercholesterolemia
PCSK9-i
medicine.disease
Phenotype
Endocrinology
Internal medicine
medicine
PCSK9-i, LDL-c, familial hypercholesterolemia
LDL-c
Cardiology and Cardiovascular Medicine
business
Alirocumab

Tools